Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.

Schäfer A, Scheurlen M, Seufert J, Keicher C, Weissbrich B, Rieger P, Kraus MR.

J Hepatol. 2010 Jan;52(1):10-5. doi: 10.1016/j.jhep.2009.10.007. Epub 2009 Oct 21.

PMID:
19897271
2.

[Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].

Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M.

Encephale. 2009 Oct;35(5):477-83. doi: 10.1016/j.encep.2007.09.007. Epub 2008 Jun 12. French.

PMID:
19853722
3.

Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.

Udina M, Moreno-España J, Navinés R, Giménez D, Langohr K, Gratacòs M, Capuron L, de la Torre R, Solà R, Martín-Santos R.

Psychoneuroendocrinology. 2013 Sep;38(9):1803-13. doi: 10.1016/j.psyneuen.2013.03.007. Epub 2013 Apr 6.

PMID:
23571152
4.

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.

Kraus MR, Schäfer A, Schöttker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M.

Gut. 2008 Apr;57(4):531-6. Epub 2007 Dec 13.

PMID:
18079286
5.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
6.

Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment.

Staufer K, Scherzer TM, Miehsler W, Reichhold D, Kienbacher C, Ferenci-Förster D, Hagmann M, Ferenci P, Moser G.

Antivir Ther. 2015;20(5):501-6. doi: 10.3851/IMP2931. Epub 2015 Jan 9.

PMID:
25573901
7.

Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C.

Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch KP, Scheurlen M.

Gastroenterology. 2007 Apr;132(4):1279-86. Epub 2007 Feb 25.

PMID:
17408646
8.

DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.

Vabo IL, Ferreira LE, Pace FH.

Arq Gastroenterol. 2016 Jan-Mar;53(1):20-4. doi: 10.1590/S0004-28032016000100005.

9.
10.
11.

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, Lok AS, Stoddard AM; HALT-C Trial Group.

Am J Gastroenterol. 2008 Nov;103(11):2766-75. doi: 10.1111/j.1572-0241.2008.02106.x. Epub 2008 Aug 21.

12.
13.

De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.

Martín-Santos R, Díez-Quevedo C, Castellví P, Navinés R, Miquel M, Masnou H, Soler A, Ardevol M, García F, Galeras JA, Planas R, Solà R.

Aliment Pharmacol Ther. 2008 Feb 1;27(3):257-65. Epub 2007 Nov 6.

14.

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M, Ziemer M, Gutsche J, Weich V, Halangk J, Berg T.

Hepatology. 2007 Oct;46(4):991-8.

PMID:
17668880
15.

[Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C].

Qi M, Zhou B, Su M, Pan J, Zhang H.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Jul;33(7):1012-6. Chinese.

16.

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.

de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA, Weegink CJ, Hengeveld MW, Janssen HL.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1306-17. doi: 10.1111/j.1365-2036.2011.04867.x. Epub 2011 Oct 17. Erratum in: Aliment Pharmacol Ther. 2012 Apr;35(7):864.

17.
18.

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.

Akhan SC, Kalender B, Ruzgar M.

Infection. 2008 Aug;36(4):341-4. doi: 10.1007/s15010-008-7134-z. Epub 2008 Jul 15.

PMID:
18629437
19.

Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C.

Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P.

Neurosci Lett. 2004 Jul 22;365(2):87-91.

PMID:
15245784
20.

Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.

Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.

J Viral Hepat. 2009 Mar;16(3):168-77. doi: 10.1111/j.1365-2893.2008.01059.x. Epub 2008 Oct 17.

PMID:
19175874

Supplemental Content

Support Center